Cabaletta Bio, Inc.

As of June 30, 2026, Cabaletta Bio, Inc. carries a market capitalization of 8.81B, placing it among publicly traded companies globally. Its enterprise value stands at 5.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cabaletta Bio, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Cabaletta Bio, Inc. has 161.31M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Cabaletta Bio, Inc. maintains a current ratio of 5.79, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.21, indicating elevated leverage, while an interest coverage ratio of -80.33 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cabaletta Bio, Inc. posted a negative return on equity (ROE) of -93.20, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -75.36, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 157.25, a quick read on workforce productivity versus industry peers.

As of the close on June 9, 2026, Cabaletta Bio, Inc.'s stock has gained approximately 50.47% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Cabaletta Bio, Inc. generated - - in revenue and converted that into -3.17B in net income, yielding earnings per share of -28.28. EBITDA reached -3.22B, while operating income came in at -3.24B.

As of June 30, 2026, Cabaletta Bio, Inc. holds 3.93B in cash and equivalents against 449.25M in total debt, resulting in a net debt position of -3.93B. Total book value stands at 3.68B, with working capital of 3.34B providing operational flexibility.

Cabaletta Bio, Inc. produced -2.69B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.94M in capital expenditures, free cash flow totaled -2.69B - equivalent to -24.05 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -44.02: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -36.23, meaning Cabaletta Bio, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Cabaletta Bio, Inc. has an Altman Z-Score of 1.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.